NCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
Clinical Trials
8 trialsNCT00936611 2021-01-28
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT02290431 2019-11-18
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Novartis
Phase 2 Completed
NCT01083602 2017-12-21
MACS1271
Novartis
Phase 2 Completed
NCT00978432 2016-11-25
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Duke University
Phase 2 Terminated
NCT00967044 2015-02-26
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01090973 2013-12-16
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated